Resmetirom (Rezdiffra, MGL-3196)

Resmetirom is an orally-administered small molecule that selectively activates the thyroid hormone receptor beta (TR-β) isoform predominantly in liver tissue. It is the first medication FDA-approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) — the inflammatory liver disease that develops in a subset of patients with non-alcoholic fatty liver disease (NAFLD) and which is increasingly common in obese and diabetic populations.

Important framing: resmetirom is not a peptide. It is a small organic molecule with a chemical structure unrelated to peptide therapeutics. It is covered on this site because of strong relevance to the metabolic-medicine audience — specifically the GLP-1 receptor agonist user community. The peptide-community classification is functional (where the discussion happens) rather than chemical.

The brand name is Rezdiffra (Madrigal Pharmaceuticals). Development codes include MGL-3196 (the original Roche name).

Resmetirom emerged from Roche's thyroid hormone receptor research program in the 2000s and was subsequently licensed to and developed by Madrigal Pharmaceuticals. The molecule is a deliberate engineering response to the long-standing problem of unselective thyroid hormone activation: thyroid hormone (T3) has powerful effects on hepatic lipid metabolism that would be therapeutically useful for dyslipidemia and fatty liver disease, but unselective T3 activation produces cardiovascular toxicity (tachycardia, atrial fibrillation), bone loss, and muscle weakness — making it untenable as a chronic therapy.

The solution was selectivity along two axes: receptor selectivity (TR-beta over TR-alpha — TR-alpha mediates most of the cardiovascular and skeletal effects, TR-beta mediates the hepatic metabolic effects) and tissue distribution (liver-selective accumulation through first-pass uptake). Resmetirom was specifically engineered to deliver liver-selective TR-beta activation with minimal extrahepatic exposure.

Phase 2 (MAESTRO-NAFLD-1, 2019) showed substantial hepatic fat reduction and improvements in liver injury and lipid markers. Phase 3 MAESTRO-NASH (results 2023) demonstrated meaningful improvements in MASH resolution and fibrosis on liver biopsy — the histologic endpoints that FDA required for approval. Approval came in March 2024 under the brand name Rezdiffra.

Thyroid hormone (T3) has powerful effects on hepatic metabolism mediated through TR-β activation:

• Increased LDL receptor expression — drives hepatic uptake of circulating LDL cholesterol, lowering serum LDL levels.
• Increased hepatic fatty acid oxidation — drives the breakdown of triglycerides accumulated in hepatocytes, reducing hepatic steatosis.
• Increased mitochondrial biogenesis — supports the metabolic capacity needed for sustained fatty acid oxidation.
• Modulated lipogenesis and SREBP signaling — affects the balance between fat synthesis and fat oxidation in the liver.

The cumulative effect is reduction in hepatic triglyceride content (measured by MRI-PDFF), improvement in MASH histologic features (steatosis, inflammation, hepatocyte ballooning), and reduction in fibrosis progression in some patients. The serum lipid effects (LDL reduction, ApoB reduction) are bonus extrahepatic benefits.

The "metabolic rate elevation" framing that has driven biohacker interest is partially accurate but importantly qualified: resmetirom is not a systemic metabolic rate accelerator (unlike DNP or mitochondrial uncouplers). The liver-selectivity means that hepatic metabolic activity increases, but systemic basal metabolic rate elevation — the effect that would drive significant weight loss — is much more modest than what unselective thyroid hormone activation would produce. The MAESTRO trial weight-loss data is modest (~1-2 kg average), reflecting this. Resmetirom is a hepatic disease treatment, not a weight-loss drug.

Resmetirom is administered orally once daily, typically with food. Bioavailability is reasonable; the molecule undergoes substantial first-pass hepatic uptake, which contributes to its liver-selective effects. Elimination half-life is approximately 24 hours, supporting once-daily dosing. The compound is metabolized through hepatic cytochrome P450 pathways (primarily CYP2C8) with implications for drug interactions.

The dose-finding work established 80 mg and 100 mg daily as the approved doses, with the higher dose used for patients with higher body weight.

The peer-reviewed literature on Resmetirom is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).

This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.

FDA-approved administration is oral once daily, dosing weight-based (80 mg for under 100 kg, 100 mg for 100 kg and above). The drug is taken with or without food per labeling. Clinician monitoring includes baseline and periodic liver function tests, thyroid function tests (the TR-β selectivity reduces but doesn't eliminate effects on the thyroid axis), and lipid panels.

The drug is supplied through specialty pharmacy distribution given the cost and the requirement for MASH diagnostic confirmation. Insurance coverage has been variable through 2024-2025.

Resmetirom is a clinically meaningful advance in MASH treatment and the first FDA-approved drug for that indication. For the metabolic-medicine audience, it represents the arrival of the thyromimetic class as a real therapeutic option in metabolic disease — distinct from the GLP-1 receptor agonist class and operating on complementary biology (hepatic disease and lipid metabolism vs appetite regulation and weight loss). The two classes pair mechanistically — see our GLP-1 + Thyromimetic stack page for the combination story.

The honest framing for biohacker interest: resmetirom is not a weight-loss drug and the "metabolic rate elevation" claim is mechanistically constrained by the liver-selectivity. Patients with MASH and overlapping obesity may benefit from the combination of a GLP-1 and resmetirom under clinician supervision; patients without confirmed MASH should not pursue resmetirom as a weight-loss strategy. The next-generation thyromimetic VK2809 (Phase 2b) and the controlled mitochondrial uncoupler HU6 (Phase 2) reflect the broader emerging story of output-side metabolic intervention.